22q11.2 Deletion Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

22q11.2 Deletion Syndrome Market Outlook

Thelansis’s “22q11.2 Deletion Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential 22q11.2 Deletion Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

22q11.2 Deletion Syndrome Overview

22q11.2 deletion syndrome (DS 22q11.2), also known by several other names, such as “DiGeorge syndrome” and “velocardiofacial syndrome”, is a rare genetic disorder caused by a deletion of the long arm of chromosome 22, specifically at locus q11.2. This deletion is most commonly a 3 million base pair deletion caused by non-allelic meiotic recombination during ovogenesis or spermatogenesis. In most cases, there are no other cases in the family (de novo), but in about 10% of cases, the syndrome is inherited from a parent. The risk of recurrence between siblings in a de novo case is 2–3% due to low-grade parental germline mosaicism. Affected individuals have a 50% risk of having an affected child. The TBX1 gene is one of the main genes involved in the typical abnormalities associated with the disorder, including the development of the bone structure of the face and neck, the development of large arteries, the structure of the ears, and the development of the thymus and parathyroids. The CRKL gene is also involved. The clinical manifestations include congenital heart defects, chronic infections, developmental and speech delays, learning deficits, and behavioural abnormalities. The diagnosis can be made by detecting cardiac anomalies by ultrasound or genetic testing. The differential diagnoses for this disease include the Smith–Lemli–Opitz, CHARGE, Alagille, VATER and Goldenhar syndromes and isotretinoin embryopathy, as these rare diseases have clinical links with 22q11.2 deletion syndrome. The prognosis of 22q11.2 deletion syndrome is variable and will depend on the severity of the disorder. In infant patients, mortality is relatively low (around 4%), and in adults, mortality is higher than in the general adult population. There is currently no curative treatment for this disease.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: 22q11.2 Deletion Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034